| Overview |
| bs-11655R-APC |
| Aggrecan Polyclonal Antibody, APC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Specifications |
| APC |
| Rabbit |
| KLH conjugated synthetic peptide derived from Human Aggrecan |
| 601-700/2415 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| P16112 |
| Secreted, Cell membrane, Extracellular matrix |
| AGC1; CSPG1; MSK16; Cartilage-specific proteoglycan core protein; CSPCP; Aggrecan core protein; Chondroitin sulfate proteoglycan 1 |
| The large chondroitin sulfate proteoglycan, aggrecan, is the predominant proteoglycan present in cartilage. Aggrecan is a member of the chondroitin sulphate proteoglycan family, which also includes versican/PG-M, neurocan and brevican. Aggrecan is a complex multidomain macromolecule that undergoes extensive processing and post-translational modification. Aggrecan in cartilage forms aggregates with hyaluronan and link protein, embedded in a collagen network. Aggrecan accounts for the compressive stiffness and resilience of the hyaline cartilage. Many forms of inflammatory arthritis are shown to be accompanied with aggrecan degradation and loss from the cartilage. Brevican is a brain proteoglycan of the aggrecan/versican/neurocan family. In the adult brain, the brevican core protein undergoes proteolytic cleavage and exists as a full-length form a carboxy-terminal fragment and an amino-terminal fragment. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz